PubHive Adds Auto-Scheduling for Recurring Aggregate Safety Reports

Cloud-based software platform PubHive Navigator now supports auto-scheduling of aggregate safety reports plus bulk assignments of responsible report owners

physIQ and CellCarta Collaborate to Accelerate a More Precise, Personalized Approach to Vaccine Development

physIQ, a pioneer in digital medicine, and CellCarta, a global leader in precision medicine services, announce a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development.

Curebase and CoBTeK (team from Côte d’Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy

Curebase and CoBTeK (team from Côte d’Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy

MicrobioSeq Releases PCR-based Microbial Antibiotic Resistance Gene Analysis Service

MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics MicrobioSeq is committed to delivering comprehensive microbial solutions to human health, agriculture, the environment, and industry by characterizing microbiomes and leveraging microorganisms. The company has recently announced the launch of PCR-based microbial antibiotic resistance gene analysis service to help researchers develop new antimicrobial medicines to address the worldwide threat of antibiotic resistance.

CD Genomics: Bioinformatics-Analysis Division Provides Genotyping Analysis Service for Studying Genetic Variations

CD ComputaBio Launches Homology Modeling Service for Drug Screening and Discovery

As a reliable computational biology service provider based in New York, CD ComputaBio has recently launched homology modeling service to help researchers deeply understand the structure-activity relationship of the target protein, and provide strong support for structure-based rational drug design, protein function research, and protein engineering research. Relying on its professional team and advanced technology, as well as high-quality products and services, CD ComputaBio has gained a solid reputation.

CD ComputaBio Releases Molecular Docking Service for Enzymology Research and Drug Design

CD ComputaBio, a reliable computational biology service provider located in New York, always hammers at researches and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. Recently, the product manager announced the launch of molecular docking service, which has a wide range of applications in the field of enzymology research and drug design.

Postdoctoral Program offers scientists unique opportunity to start their computational chemistry career

Firstsource Named Best in KLAS® for Eligibility and Enrollment Services

Firstsource Solutions Limited, a global provider of Business Process Management (BPM) services and an RP-Sanjiv Goenka Group company, was ranked #1 in the 2022 Best in KLAS®: Software & Services Report, and noted as a leader in the Eligibility and Enrollment Services category.

PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy

MDI Biological Laboratory Scientist Identifies Mechanism Underlying ‘Inflammaging’

A research team led by Samuel Beck, Ph.D., of the MDI Biological Laboratory in Bar Harbor, Maine, has identified disruption of chromatin architecture as the mechanism underlying inflammaging, a chronic, low-grade inflammatory response that has been linked to the chronic diseases of old age, including Alzheimer’s, cancer, diabetes, heart disease, macular degeneration and more, as well as to a shortened lifespan.

Rho Experts to Present at 5th Annual Gene Therapy for Rare Disorders Conference

Rho, a global full-service contract research organization (CRO), is sharing its drug development success and expertise in gene therapy research during the 5th Annual Gene Therapy for Rare Disorders Conference, taking place in Boston, Massachusetts from March 7-10. Rho’s Associate Director of Regulatory Strategy, Joseph Watson, Senior Director of Nonclinical Development, Brenda Faiola, and Research Scientist Kelsey Behrens will be giving a presentation titled, “Nonclinical Considerations to Enable a Successful Clinical Program.” The March 9 presentation at 2:00 p.m. will discuss key design and execution components, for nonclinical studies, necessary to enable clinical studies. The following items will be addressed: ü Considerations for gene therapy programs regarding animal models, dose selection, and delivery device compatibility ü Lessons Rho has learned in interacting with the FDA across various gene therapy programs ü Gene therapy approval examples that highlight key nonclinical considerations

Swiss CDMO expands capsule filling capabilities

siRNA Drug Delivery Platform of BOC RNA Speeds Up Disease Treatment Research

Huateng Pharma Provides Orlistat Intermediates CAS NO 104801-96-9 Large Scale Services

Creative Biogene: A Premier Partner in the Exploration of Pathogenesis of Mitochondrial-Associated Diseases

Creative Biogene has become the premier partner to cooperate in the exploration of the pathogenesis of mitochondrial-associated diseases.

Abzena, Alira Health and Oncodesign launch DRIVETM-Biologics to support access to specialist services from discovery to clinical development for oncology and inflammation

Pronalyse Launches Antibody Drug Conjugates (ADCs) Characterization Service for Drug Discovery

Pronalyse, a new division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services for over 10 years. Creative Proteomics Pronalyse recently announced the launch of antibody-drug conjugates (ADCs) characterization service to ensure the safety and effectiveness of ADCs drugs.

Lipidomics Bioinformation Analysis Now Available by Creative Proteomics’s Lipidomics Platform

As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnological and pharmaceutical companies. The company has recently announced the launch of fully-developed lipidomics bioinformation analysis service to screen differential lipid molecules and analyze their pathways, revealing the physiological mechanism of their changes.

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Microbial Metabolomics Solutions

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. With deep industry and business process expertise and a good reputation in providing contract services specialized for metabolomics, Creative Proteomics Metabolomics announced the launch of microbial metabolomics service to promote a comprehensive understanding of microbial physiology.